Table 1. ProGRPp in BLD, SCLC, and NSCLC.

Characteristics	n	ProGRPp (pg ml−1) Median, IQR	P-value
All benign lung diseases	102	39, 32–47
Age (years)
<63	60	35, 31–43
⩾63	42	40, 32–52	0.072
Gender
Male	60	39, 33–49
Female	42	38, 31–45	0.322
Smoking habits
Nonsmoker	52	34, 29–43
Smoker/Ex	50	41, 34–49	0.14
BLD
ILD	13	46, 40–59
DNILD	35	43, 37–52
OLD	25	35, 32–43
SPN	29	32, 29–38	<0.001
All small-cell lung carcinoma	94	705, 220–3319
Age (years)
⩽63	48	597, 211–3746
>63	46	1439, 246–3527	0.314
Gender
Female	30	551, 204–2273
Male	64	850, 223–4574	0.17
SCLC subtypes
Combined	10	713, 32–2225
Pure	84	704, 228–4351	0.418
Stage
Limited	35	568, 99–2053
Extensive	59	909, 323–5271	0.015
Weight loss (kg)
0	51	540, 179–1719
1–10	33	1860, 306–4938
>10	10	7716, 766–23 124	0.003
Performance status
0–1	67	790, 211–4553
⩾2	27	540, 291–2349	0.716
All non-small-cell lung carcinoma	243	41, 31–56
Age
⩽63	117	37, 28–51
>63	126	44, 33–62	0.009
Gender
Female	80	43, 31–57
Male	163	39, 30–56	0.43
Smoking habits
Nonsmoker	55	38, 29–57
Smoker/Ex	188	42, 32–56	0.741
Histological type
Adenocarcinoma	157	41, 29–53
Squamous	52	41, 30–54
Large cell	13	58, 35–269
Other	21	38, 26–47	0.087
Neuroendocrine features (LCNEC or NSCLC-NED)
No	225	39, 30–55
Yes	18	50, 41–678	0.01
TNM stage
I–II	26	48, 32–63
III	84	45, 33–59
IV	133	39, 30–52	0.639
Weight loss (kg)
0	159	39, 30–54
1–10	61	36, 30–51
>10	23	30, 37–49	0.53
Performance status
0–1	191	40, 30–53
⩾2	52	44, 32–63	0.197

Abbreviations: BLD=benign lung disease; DNILD=diffuse noninfectious lung disease; ILD=infectious lung disease; IQR=interquartile range; LCNEC=large-cell neuroendocrine carcinoma; NSCLC=non-small-cell lung carcinoma; NSCLC-NED=NSCLC with neuroendocrine differentiation; OLD=obstructive lung disease; ProGRPp=plasma progastrin-releasing peptide; SCLC=small-cell lung carcinoma; SPN=solitary pulmonary nodule; TNM=tumour, node, and metastasis.